和黄医药 以上内容基于公开资料整理，不构成投资建议。 分时图 日K线 周K线 月K线 23.26 0.08 0.35% 1.38% 0.91% 0.47% 0.00% 0.47% 0.91% 1.38% 22.86 22.97 23.07 23.18 23.29 23.39 23.50 09:30 10:30 12:00/13:00 14:00 16:10 0 5万 9万 14万 经济观察网和黄医药近期在业务进展与全球合规方面取得多项里程碑。公司计划于2026年3月5日举行董 事会会议审议2025年年度业绩；新型脾酪氨酸激酶抑制剂索乐匹尼布用于治疗温抗体型自身免疫性溶血 性贫血的III期研究已达到主要终点，计划在2026年上半年向中国国家药监局提交新药上市申请；抗体靶 向偶联药物候选药物HMPL-A580和HMPL-A830预计2026年启动1期临床研究；此外，凡瑞格拉替尼和 赛沃替尼的新药申请已获受理并纳入优先审评。另据浦东发布消息，和黄医药上海旗舰生产基地近日 以"零483缺陷项"通过美国食品药品管理局现场检查，进一步夯实全球供应链能力。 近7天(2026年2月7日至13日)和黄医药港股(00013)股价 ...

经济观察网 和黄医药（00013）2026年将有多项关键事件，包括年度业绩发布及重要新药研发进展。 产品研发进展 根据机构研报，公司抗体靶向偶联药物平台中的候选药物HMPL-A580和HMPL-A830预计将在2026年启 动1期临床研究。此外，公司近期管线进展还包括凡瑞格拉替尼和赛沃替尼的新药申请获受理并纳入优 先审评。 业绩经营情况 以上内容基于公开资料整理，不构成投资建议。 公司计划于2026年3月5日举行董事会会议，审议并批准截至2025年12月31日止年度的年度业绩。 业务进展情况 新型脾酪氨酸激酶抑制剂索乐匹尼布用于治疗温抗体型自身免疫性溶血性贫血的III期研究已达到主要终 点，公司计划在2026年上半年向中国国家药监局提交新药上市申请。 ...

Group 1: Key Insights - The report highlights multiple positive catalysts for the electronics sector, particularly for Huadian Co., Ltd. (002463), including the upcoming financial disclosures from overseas cloud vendors and domestic supply chain performance forecasts, which will validate the sustainability of computing power demand and industry prosperity [4] - The defense and military industry, represented by Guoke Military Industry (688543), is transitioning from conventional ammunition to intelligent and information-based ammunition, positioning the company to benefit from high industry demand and military trade orders, which are expected to drive significant growth [4] - In the pharmaceutical and biotechnology sector, Huan Huang Pharmaceutical (0013.HK) is advancing its ATTC platform with candidates entering clinical trials, including HMPL-A251, which is a first-in-class drug, and is also expanding the indications for existing drugs, indicating strong future growth potential [5] Group 2: Company-Specific Analysis - Wan Hua Chemical (600309) is reinforcing its position as a global leader in polyurethane, with significant market shares in MDI and TDI, and is expected to enhance profitability through strategic partnerships and cost advantages in its petrochemical segment [6] - Su Kan Agricultural Development (601952) anticipates a slight decline in 2025 profits due to falling grain prices, but expects a recovery driven by rising grain prices and increased farmland area through land transfer initiatives [7] - Yingwei Technology (002837) is poised for substantial growth in the server liquid cooling market, with expectations of doubling industry growth in 2026 and 2027, supported by orders from major overseas clients [8] Group 3: Financial Performance and Projections - China Pacific Insurance (601601) demonstrated strong resilience with a 11% year-on-year increase in net profit to 27.9 billion yuan, driven by robust growth in new business value in its life insurance segment [8] - Jin Jiang Shipping (601083) reported a 64% year-on-year increase in net profit for Q3, indicating strong performance relative to peers, with expectations for continued growth [8] - Xiaoshangcheng (600415) is benefiting from increased rental income and new merchant additions, with projections for profit doubling in 2026 due to enhanced service offerings and improved gross margins [8]

Core Viewpoint - HCM (HCM.US) shares rose over 5% to $16.12 following the publication of SACHI III trial results in The Lancet, highlighting the potential of savolitinib and osimertinib combination therapy for specific lung cancer patients [1] Group 1: Company Overview - HCM announced the results of the SACHI III trial, which focuses on the combination therapy of savolitinib and osimertinib for treating EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer patients who progressed after first-line EGFR TKI treatment [1] - Savolitinib is a potent and highly selective oral MET TKI co-developed by AstraZeneca and HCM, with AstraZeneca responsible for commercialization [1] - Osimertinib is an irreversible third-generation EGFR TKI [1] Group 2: Research and Approval - The SACHI study data supports the approval of the savolitinib and osimertinib combination therapy, which is expected to be granted in China by June 2025 [1]

Core Viewpoint - Hutchison China MediTech (HCM.US) shares rose over 5% to $16.12 following the publication of SACHI III trial results in The Lancet, indicating positive developments in cancer treatment [1] Group 1: Company Developments - Hutchison China MediTech announced the results of the SACHI III trial, which studied the combination therapy of savolitinib and osimertinib for treating EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer patients who progressed after first-line EGFR TKI treatment [1] - Savolitinib is a potent and highly selective oral MET TKI co-developed by AstraZeneca and Hutchison China MediTech, with AstraZeneca responsible for commercialization [1] - Osimertinib is an irreversible third-generation EGFR TKI [1] Group 2: Regulatory Approval - Based on the data from the SACHI study, the combination therapy of savolitinib and osimertinib is expected to receive approval in China by June 2025 [1]

Core Viewpoint - Hutchison China MediTech (00013) has seen its stock price increase by over 20% in the month, with a current rise of 3.68% to HKD 24.8, and a trading volume of HKD 142 million. This surge is attributed to the publication of the SACHI III study results in The Lancet, which highlights the efficacy of a combination therapy for specific lung cancer patients [1]. Group 1 - Hutchison China MediTech announced the results of the SACHI III study, which focuses on a combination therapy of savolitinib and osimertinib for treating EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer patients who have progressed after first-line EGFR TKI treatment [1]. - The SACHI study data indicates that the combination therapy of savolitinib, a potent and selective oral MET TKI co-developed with AstraZeneca, and osimertinib, an irreversible third-generation EGFR TKI, has shown promising results [1]. - Based on the findings from the SACHI study, the combination therapy is expected to receive approval in China by June 2025 [1].

Core Viewpoint - Hutchison China MediTech (00013) has seen its stock price increase by over 20% in the month, with a current rise of 3.68% to HKD 24.8, and a trading volume of HKD 142 million, following the publication of SACHI III trial results in The Lancet [1] Group 1: Company Developments - Hutchison China MediTech announced the results of the SACHI III trial, which studied the combination therapy of savolitinib and osimertinib for treating EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer patients who progressed after first-line EGFR tyrosine kinase inhibitor (TKI) treatment [1] - The SACHI trial results indicate that the combination therapy of savolitinib, a potent and selective oral MET TKI co-developed with AstraZeneca, and osimertinib, an irreversible third-generation EGFR TKI, has shown promising outcomes [1] - Based on the data from the SACHI study, the combination therapy is expected to receive approval in China by June 2025 [1]

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 3%, currently up 2.9% at HKD 24.1, with a trading volume of HKD 57.28 million, following the announcement of positive results from the SACHI III study published in The Lancet [1] Group 1: Study Announcement - The SACHI III study results involve a combination therapy of Savolitinib (赛沃替尼) and Osimertinib (奥希替尼) for treating EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer patients who have disease progression after first-line EGFR tyrosine kinase inhibitor (TKI) treatment [1] - Savolitinib is a potent, highly selective oral MET TKI co-developed by AstraZeneca and Hutchison China MediTech, and commercialized by AstraZeneca [1] - Osimertinib is an irreversible third-generation EGFR TKI [1] Group 2: Regulatory Approval - Based on the data from the SACHI study, the combination therapy of Savolitinib and Osimertinib is expected to receive approval in China by June 2025 [1]

Core Insights - A significant breakthrough in treating advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations and MET amplification has been achieved through a "dual-target" therapy combining Savolitinib and Osimertinib, offering new treatment options for patients facing resistance to targeted therapies [3][5]. Group 1: Research Findings - In China, 40%-50% of lung adenocarcinoma patients exhibit EGFR gene mutations, with MET amplification being a major cause of resistance to EGFR-targeted therapies [2][3]. - The study led by Professor Lu Shun involved 211 patients who were randomly assigned to receive either the combination therapy or standard chemotherapy, revealing a median progression-free survival of 8.2 months for the combination group compared to 4.5 months for the chemotherapy group [4]. - The risk of disease recurrence or death was reduced by 66% in the combination therapy group, with 58% of patients achieving objective response compared to 34% in the chemotherapy group [4]. Group 2: Regulatory and Clinical Impact - The combination therapy of Savolitinib and Osimertinib has received approval from the National Medical Products Administration of China for treating EGFR mutation-positive patients with advanced or metastatic non-squamous NSCLC after progression on EGFR-TKI therapy [5]. - Professor Lu Shun has led 29 domestic and international studies on lung cancer, including 17 national Class 1 new drug studies, contributing to the approval and inclusion of several innovative drugs in medical insurance [6].

Core Viewpoint - The announcement by Hutchison China MediTech Limited (和黄医药) regarding the publication of the SACHI III study results in The Lancet highlights the efficacy of the combination therapy of savolitinib and osimertinib for treating EGFR mutation-positive non-small cell lung cancer patients with MET amplification who have progressed after first-line TKI treatment [1][2]. Group 1: Study Results - The SACHI study demonstrates that the combination of savolitinib (a potent MET TKI) and osimertinib (a third-generation EGFR TKI) significantly improves treatment outcomes for patients with MET amplification [1][2]. - The data from the SACHI study indicates that the combination therapy has been approved in China as of June 2025 [1]. Group 2: Expert Commentary - Professor Lu Shun, a principal investigator of the SACHI study, emphasized that the results provide strong evidence for the effectiveness of the combination therapy in addressing MET amplification, a key resistance mechanism in challenging patient populations [2]. - The study also noted consistent efficacy in patients who had previously received third-generation EGFR TKI treatment, indicating the therapy's potential for a broader patient base [2]. - The combination therapy offers a convenient and well-tolerated all-oral treatment option for patients in need of new therapies [2].